Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen to Screen Third Party Cell-Culture Technologies; Clarifies Viropro Deal

NEW YORK (GenomeWeb News) — Invitrogen has started a new program to screen technologies from third party companies against its own cell-culture products, the company said today.
Invitrogen also clarified the terms of its recent collaboration with Viropro, which falls under this screening program, saying it would not pay royalties or take commercial interest in any licensing of the technologies.
Invitrogen said it will evaluate GIBCO cell-culture media products and platforms offered by PD-Direct Bioprocess Services along with the outside technologies.
The program is a “unique approach” for evaluating performance of cell-culture products, Jeff Greenberg, vice president of Invitrogen’s BioProduction business, said in a statement.
The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.